Cited by

• Biocompatible Naringin loaded low molecular peptide Nanogels are effective against human melanoma cells.

  Secerli J, Karayavuz B, Aksoy R, Erdoğan H, Bacanlı MG. Secerli J, et al. Toxicol Res (Camb). 2024 Nov 7;13(6):tfae185. doi: 10.1093/toxres/tfae185. eCollection 2024 Dec. Toxicol Res (Camb). 2024. PMID: 39524611
• A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma.

  Gouda MA, Stephen B, Tian Y, Alshawa A, Onwugaje DOC, Albittar A, Yang Y, Zarifa A, Yilmaz B, Gurses S, Sprenger A, Derbala MH, Brink A, How JA, Moyers J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Patel SP, Oliva IG. Gouda MA, et al. J Immunother Precis Oncol. 2024 Nov 1;7(4):247-254. doi: 10.36401/JIPO-24-3. eCollection 2024 Nov. J Immunother Precis Oncol. 2024. PMID: 39524469 Free PMC article.
• Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy.

  Forsthuber A, Aschenbrenner B, Korosec A, Jacob T, Annusver K, Krajic N, Kholodniuk D, Frech S, Zhu S, Purkhauser K, Lipp K, Werner F, Nguyen V, Griss J, Bauer W, Soler Cardona A, Weber B, Weninger W, Gesslbauer B, Staud C, Nedomansky J, Radtke C, Wagner SN, Petzelbauer P, Kasper M, Lichtenberger BM. Forsthuber A, et al. Nat Commun. 2024 Nov 8;15(1):9678. doi: 10.1038/s41467-024-53908-9. Nat Commun. 2024. PMID: 39516494 Free PMC article.
• Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.

  Ou Y, Liang S, Gao Q, Shang Y, Liang J, Zhang W, Liu S. Ou Y, et al. Front Immunol. 2024 Oct 18;15:1482746. doi: 10.3389/fimmu.2024.1482746. eCollection 2024. Front Immunol. 2024. PMID: 39493767 Free PMC article.
• Perspectives of patients, partners, primary and hospital-based health care professionals on living with advanced cancer and systemic treatment.

  Kolsteren EEM, Deuning-Smit E, Prins JB, van der Graaf WTA, Kwakkenbos L, Custers JAE. Kolsteren EEM, et al. J Cancer Surviv. 2024 Oct 29. doi: 10.1007/s11764-024-01698-w. Online ahead of print. J Cancer Surviv. 2024. PMID: 39470942